Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

  • £ 395,000 FUNDED SO FAR (79 %)
  • £ 532,082 MAXIMUM TARGET
  • 21.07% EQUITY
  • 43 DAYS
  • SIGN IN TO SEE MORE
79%

MEDWISE AI LTD - Investment Opportunity

Medwise.ai uses Artificial Intelligence to answer questions for clinicians faster than ever before. Currently, doctors cannot keep up with the latest research evidence, which means they can't provide the best care for their patients. Health care providers in the US are losing 3% of their revenue due to lack of adoption of evidence-based best practice, and in the UK this translates to the NHS losing £5bn every year. Medwise.ai utilises the latest transformer based neural networks and other Natural Language Processing technology to extract answers from multiple sources and support clinicians to make the best decisions for patients. The founders have experience at NHS, Google and Amazon.

LIVE PITCHING

Medwise.ai's CEO and co-founder Keith Tsui presenting at one of Angel Den's pitching events. Please see this link for answers to questions which did not get answered in the event: https://docs.google.com/document/d/157kt3p9SWlf0-WHH5Dg3U4Dkp3xpIL4fm0jyZ-4E9n4/edit?usp=sharing

You have to log in or register to see this information.
INTERVIEW WITH ENTREPRENEUR

Interview with co-founder and CEO Keith Tsui

THE IDEA
Products & Services

Medwise.ai utilises the latest advancements in natural language processing technologies, including transformer-based neural networks, to instantly search and retrieve clinical answers from biomedical journal articles and clinical guidelines for clinicians. It provides quick, concise and relevant answers to clinicians. Unlike traditional search engines that provide you with a list of websites or documents, the product provides bite-sized, actionable and evidence-based answers extracted from trusted sources. Powered by AI, the product continues to improve as more user data is collected.

Problem Solved

Currently, clinicians abandon 50% of their clinical questions due to time pressure and lack of good search tools. Without the right answers at the right time, not all patients receive the best practice care from their health care provider and could suffer from poor patient outcomes and increased downstream costs to the provider. Unwarranted variation in care costs the NHS £5 billion every year and costs the US healthcare system $105 billion every year. Medwise.ai utilise the latest advances in artificial intelligence software to help clinicians make better clinical decisions. 

Revenue Model

Medwise.ai partners with healthcare organisations and pharmaceutical companies to tailor our product for their needs and challenges around specific disease areas. The solution is sold through a B2B SaaS model and there is interest from 3 pharmaceutical companies, a telemedicine company and a NHS hospital to trial the solution.

Exit Strategy
You have to log in or register to see this information.
Minimum Target £ 500,000 Maximum Target £ 532,082 Minimum investment amount £ 10,000 Maximum investment amount £ 50,000
Share On Website Visit site Location OAKHAM
Gallery

The Idea

Products & Services

Medwise.ai utilises the latest advancements in natural language processing technologies, including transformer-based neural networks, to instantly search and retrieve clinical answers from biomedical journal articles and clinical guidelines for clinicians. It provides quick, concise and relevant answers to clinicians. Unlike traditional search engines that provide you with a list of websites or documents, the product provides bite-sized, actionable and evidence-based answers extracted from trusted sources. Powered by AI, the product continues to improve as more user data is collected.

Problem Solved

Currently, clinicians abandon 50% of their clinical questions due to time pressure and lack of good search tools. Without the right answers at the right time, not all patients receive the best practice care from their health care provider and could suffer from poor patient outcomes and increased downstream costs to the provider. Unwarranted variation in care costs the NHS £5 billion every year and costs the US healthcare system $105 billion every year. Medwise.ai utilise the latest advances in artificial intelligence software to help clinicians make better clinical decisions. 

Revenue Model

Medwise.ai partners with healthcare organisations and pharmaceutical companies to tailor our product for their needs and challenges around specific disease areas. The solution is sold through a B2B SaaS model and there is interest from 3 pharmaceutical companies, a telemedicine company and a NHS hospital to trial the solution.

Exit Strategy
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
  • £ 395,000 FUNDED SO FAR (79 %)
  • £ 532,082 MAXIMUM TARGET
  • 21.07% EQUITY
  • 43 DAYS
  • SIGN IN TO SEE MORE
79%